Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The antiviral treatment is safe and effective for pediatric patients ages 12 and up.
People with HIV are at greater risk for hepatitis B but are less likely to get vaccinated and respond to vaccines.
The new drug reduced HDV viral load and lowered liver enzyme levels in people with hepatitis B and D.
Paxlovid and molnupiravir can reduce the risk of severe COVID-19, but they must be started within five days of symptom onset.
Molnupiravir is authorized for people at high risk for severe COVID-19 when other treatment options are not available.
Paxlovid, which reduces the risk of hospitalization or death by about 90%, is expected to be a game-changer.
The new drugs must be used within a narrow window of time after developing symptoms.
Molnupiravir reduces severe illness and death, but it must be started within days after developing symptoms.
Post-exposure and pre-exposure prophylaxis could be a game-changer for immunocompromised people.
People under 50 who were cured of hepatitis C were at comparable risk to the general population.
The government-wide effort aims to develop the next generation of COVID-19 treatments to prepare the U.S. to respond to future virus threats
Positive diagnostic tests and drug prescriptions dropped 40% in July 2020 compared with earlier years.
Suppression of hepatitis B virus with antiviral treatment lowered the risk of hepatocellular carcinoma by 58%.
Assessing patient-reported outcomes can support treatment for hard-to-reach populations.
People who received treatment had a lower composite risk of cirrhosis, liver cancer and death.
The risk was lower in people who had achieved a sustained virological response compared with those who had not.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.